GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Briacell Therapeutics BCTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.73

-5.57%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Briacell Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Briacell Therapeutics is based in West Vancouver, British Columbia, Canada and is incorporated in British Columbia, Canada. Its shares trade on Nasdaq under the ticker BCTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 July 2026, it reported a net loss of $34.9m. At that date it held total assets of $23.6m and shareholders' equity of $15.6m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
24 Feb 2021
Employees
22
Head office
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, A1, V7T 2X1
Incorporated in
A1
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Bria-IMT is in Phase 3 clinical trials for end-stage breast cancer treatment.
  • Bria-OTS is a personalized off-the-shelf immunotherapy developed with MSK Accelerator.
  • BriaCell Therapeutics has a license agreement with University of Maryland for soluble CD80 development.

Weaknesses

  • BriaCell Therapeutics has only 22 employees in the Health Care sector.
  • The company is pre-clinical stage with no approved products yet.
  • BriaCell Therapeutics is listed on the stock market since 2021.

Opportunities

  • Bria-OTS+ is being developed for metastatic breast cancer and prostate cancer indications.
  • BriaCell Therapeutics collaborates with MSK Accelerator for accelerated clinical development.
  • The soluble CD80 therapeutic acts as an immune checkpoint inhibitor for cancer treatment.

Threats

  • Bria-IMT is in Phase 3 clinical trials which require significant funding.
  • BriaCell Therapeutics faces competition in the Health Care sector.
  • The company's pre-clinical stage may delay product commercialization.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.